ProCE Banner Activity

HER2-, HER3-, and TROP2-Targeted ADCs: Latest Progress, Future Possibilities, and Advancing the Therapeutic Relational Connection

Slideset

Download this slideset from expert advanced practice providers with the latest about HER2-, HER3-, and TROP2-targeted ADCs in the care of patients with solid tumors, including mechanisms of action, clinical considerations/adverse event management, and patient counseling recommendations.

Released: November 11, 2024

Expiration: November 10, 2025

Share

Provided by

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Gilead Sciences, Inc.

AstraZeneca

Gilead Sciences, Inc.

Partners

Clinical Care Options, LLC

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner